PDL BioPharma Gross Profit 2010-2020 | PDLI

PDL BioPharma gross profit from 2010 to 2020. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
PDL BioPharma Annual Gross Profit
(Millions of US $)
2020 $
2019 $1
2018 $150
2017 $290
2016 $240
2015 $590
2014 $581
2013 $456
2012 $381
2011 $362
2010 $345
2009 $318
PDL BioPharma Quarterly Gross Profit
(Millions of US $)
2020-12-31
2020-06-30 $3
2020-03-31 $3
2019-12-31 $-33
2019-09-30 $29
2019-06-30 $3
2019-03-31 $3
2018-12-31 $34
2018-09-30 $56
2018-06-30 $32
2018-03-31 $28
2017-12-31 $50
2017-09-30 $57
2017-06-30 $139
2017-03-31 $43
2016-12-31 $66
2016-09-30 $54
2016-06-30 $21
2016-03-31 $103
2015-12-31 $178
2015-09-30 $125
2015-06-30 $138
2015-03-31 $150
2014-12-31 $117
2014-09-30 $165
2014-06-30 $163
2014-03-31 $137
2013-12-31 $116
2013-09-30 $100
2013-06-30 $149
2013-03-31 $92
2012-12-31 $92
2012-09-30 $85
2012-06-30 $126
2012-03-31 $77
2011-12-31 $73
2011-09-30 $84
2011-06-30 $122
2011-03-31 $83
2010-12-31 $76
2010-09-30 $86
2010-06-30 $120
2010-03-31 $62
2009-12-31 $58
2009-09-30 $71
2009-06-30 $126
2009-03-31 $63
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.995B 9.34
GSK (GSK) United Kingdom $82.506B 9.91
Bio-Rad Laboratories (BIO.B) United States $16.008B 35.37
QIAGEN (QGEN) Netherlands $11.286B 18.90
Biohaven Pharmaceutical Holding (BHVN) United States $10.366B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.454B 0.00
Arcus Biosciences (RCUS) United States $1.972B 38.49
Emergent Biosolutions (EBS) United States $1.578B 9.15
Myovant Sciences (MYOV) United Kingdom $1.450B 0.00
Zymeworks (ZYME) Canada $0.376B 0.00
Enzo Biochem (ENZ) United States $0.123B 0.00
Gelesis Holdings (GLS) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
Ambrx Biopharma (AMAM) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00